A phase 1 clinical study in Europe with ENA-001 utilizing an intravenous (IV) formulation.
Latest Information Update: 24 Jan 2025
Price :
$35 *
At a glance
- Drugs ENA-001 (Primary)
- Indications Apnoea; COVID-19 respiratory infection; Respiration disorders
- Focus Adverse reactions
- 24 Jan 2025 New trial record